Hormonal
Tirzepatide 15 mg provides statistically significant improvements in cardiometabolic risk factors, including waist circumference, fasting plasma glucose, and triglycerides, compared to semaglutide 2.4 mg.
Beyond weight loss, tirzepatide 15mg offers superior benefits for heart health markers like waist size, blood sugar (fasting), and triglycerides compared to semaglutide 2.4mg. This makes it a strong option for patients concerned about cardiovascular risk factors associated with obesity and diabetes.
Tirzepatide 15 mg was associated with statistically significant improvements in several cardiometa- bolic risk factors, including waist circumference, fasting plasma glucose and triglycerides.
Why this rating
Derived from the same robust ITC methodology as the primary claim.
Source
Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes
Andreea Ciudin et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.16508
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →